Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and Therapeutic Considerations

키워드

참고문헌 (115)

1. Schwarcz R, "The kynurenine pathway and the brain : challenges, controversies and promises", Neuropharmacology, 112(Pt B), pp.237~247 (2017)
2. Kim YK, "Neuroinflammation and the immune-kynurenine pathway in anxiety disorders", Curr Neuropharmacol, 16, pp.574~582 (2018)
3. da Silveira TL, "Quinolinic acid and glutamatergic neurodegeneration in caenorhabditis elegans", Neurotoxicology, 67, pp.94~101 (2018)
4. Tufvesson-Alm M, "Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons : relevance for schizophrenia", Neuropharmacology, 138, pp.130~139 (2018)
5. Majewski M, "Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease", J Physiol Pharmacol, 67, pp.3~19 (2016)
6. Sas K, "Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection", Molecules, 23, pp.191~ (2018)
7. Allen AP, "Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression : comparison of multiple ketamine infusions and electroconvulsive therapy", J Psychiatr Res, 100, pp.24~32 (2018)
8. Benedetti F, "Neuroinflammation in bipolar depression", Front Psychiatry, 11, pp.71~ (2020)
9. Price JB, "Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression", Neurosci Biobehav Rev, 90, pp.212~220 (2018)
10. Cervenka I, "Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health", Science, 357, pp.eaaf9794~ (2017)
11. Qin Y, "IDO and TDO as a potential therapeutic target in different types of depression", Metab Brain Dis, 33, pp.1787~1800 (2018)
12. Erhardt S, "The kynurenine pathway in schizophrenia and bipolar disorder", Neuropharmacology, 112(Pt B), pp.297~306 (2017)
13. Zakrocka I, "Influence of cyclooxygenase-2 inhibitors on kynurenic acid production in rat brain in vitro", Neurotox Res, 35, pp.244~254 (2019)
14. Fallarini S, "Expression of functional GPR35 in human iNKT cells", Biochem Biophys Res Commun, 398, pp.420~425 (2010)
15. Flis M, "The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia", Pol Merkur Lekarski, 41, pp.160~164 (2016)
16. Pierozan P, "Cytoskeleton as a target of quinolinic acid neurotoxicity : insight from animal models", Mol Neurobiol, 55, pp.4362~4372 (2018)
17. Santana-Martínez RA, "The therapeutic effect of curcumin in quinolinic acid-induced neurotoxicity in rats is associated with BDNF, ERK1", 2, Nrf2, and antioxidant enzymes, 2019, pp.8, 388~
18. Jacobs KR, "Inhibiting the kynurenine pathway in spinal cord injury: multiple therapeutic potentials?", Neural Regen Res, 13, pp.2073~2076 (2018)
19. Romain Troubat, "Neuroinflammation and depression: A review", European Journal of Neuroscience, 53(1), pp.151~171 (2021), Wiley[DOI]
20. Pedersen BK, "Physical activity and muscle-brain crosstalk", Nat Rev Endocrinol, 15, pp.383~392 (2019)
21. Guillemin GJ, "Quinolinic acid, the inescapable neurotoxin", FEBS J, 279, pp.1356~1365 (2012)
22. Raison CL, "CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha : relationship to CNS immune responses and depression", Mol Psychiatry, 15, pp.393~403 (2010)
23. Baranyi A, "Beta-trace protein as a new non-invasive immunological marker for quinolinic acid-induced impaired blood-brain barrier integrity", Sci Rep, 7, pp.43642~ (2017)
24. Al-Hakeim HK, "Plasma indoleamine-2, 3-dioxygenase(IDO)is increased in drugnaïve major depressed patients and treatment with sertraline and ketoprofen normalizes IDO in association with pro-inflammatory and immune-regulatory cytokines", CNS Neurol Disord Drug Targets, 19, pp.44~54 (2020)
25. Zoga M, "Indoleamine 2, 3-dioxygenase and immune changes under antidepressive treatment in major depression in females", In Vivo, 28, pp.633~638 (2014)
26. Martín-Hernández D, "Chronic mild stress alters kynurenine pathways changing the glutamate neurotransmission in frontal cortex of rats", Mol Neurobiol, 56, pp.490~501 (2019)
27. Connor TJ, "Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?", Neurosci Lett, 441, pp.29~34 (2008)
28. Borsini A, "Rescue of IL-1-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants", Brain Behav Immun, 65, pp.230~238 (2017)
29. Myint AM, "Network beyond IDO in psychiatric disorders : revisiting neurodegeneration hypothesis", Prog Neuropsychopharmacol Biol Psychiatry, 48, pp.304~313 (2014)
30. Adams S, "Involvement of the kynurenine pathway in human glioma pathophysiology", PLoS One, 9, pp.e112945~ (2014)
31. Dantzer R, "Role of the kynurenine metabolism pathway in inflammation-induced depression : preclinical approaches", Curr Top Behav Neurosci, 31, pp.117~138 (2017)
32. Kanchanatawan B, "Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite(TRYCAT)pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid", Mol Neurobiol, 55, pp.1524~1536 (2018)
33. Braidy N, "Kynurenine pathway metabolism and neuroinflammatory disease", Neural Regen Res, 12, pp.39~42 (2017)
34. Savitz J, "The kynurenine pathway : a finger in every pie", Mol Psychiatry, 25, pp.131~147 (2020)
35. Walker AK, "NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL", 6J mice, 2013, pp.38, 1609~1616
36. Sayson LV, "The novel methoxetamine analogs N-ethylnorketamine hydrochloride(NENK), 2-MeO-N-ethylketamine hydrochloride(2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride(4-MeO-NEK)elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors", Psychopharmacology(Berl), 236, pp.2201~2210 (2019)
37. Wu W, "Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression : a preliminary study", Sci Rep, 7, pp.40530~ (2017)
38. Leday GGR, "Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder", Biol Psychiatry, 83, pp.70~80 (2018)
39. Małyszczak K, "Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C", Adv Clin Exp Med, 28, pp.1217~1222 (2019)
40. Maes M, "Increased IgA and IgM responses against gut commensals in chronic depression : further evidence for increased bacterial translocation or leaky gut", J Affect Disord, 141, pp.55~62 (2012)
41. Huang M, "Longitudinal association of inflammation with depressive symptoms : a 7-year cross-lagged twin difference study", Brain Behav Immun, 75, pp.200~207 (2019)
42. Vallerand IA, "Assessment of a bidirectional association between major depressive disorder and alopecia areata", JAMA Dermatol, 155, pp.475~479 (2019)
43. Li H, "Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder", J Affect Disord, 241, pp.305~310 (2018)
44. Suzuki H, "Suicide and microglia : recent findings and future perspectives based on human studies", Front Cell Neurosci, 13, pp.31~ (2019)
45. Lawson MA, "Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2, 3-dioxygenasedependent depression-like behaviors", J Neuroinflammation, 10, pp.87~ (2013)
46. Salazar A, "Indoleamine 2, 3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge", Horm Behav, 62, pp.202~209 (2012)
47. Parrott JM, "Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation", Transl Psychiatry, 6, pp.e918~ (2016)
48. Garrison AM, "Kynurenine pathway metabolic balance influences microglia activity : targeting kynurenine monooxygenase to dampen neuroinflammation", Psychoneuroendocrinology, 94, pp.1~10 (2018)
49. Wichers MC, "IDO and interferon-alpha-induced depressive symptoms : a shift in hypothesis from tryptophan depletion to neurotoxicity", Mol Psychiatry, 10, pp.538~544 (2005)
50. Baranyi A, "Quinolinic acid responses during interferon--induced depressive symptomatology in patients with chronic hepatitis c infection-a novel aspect for depression and inflammatory hypothesis", PLoS One, 10, pp.e0137022~ (2015)
51. Parrott JM, "Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge", J Neuroinflammation, 13, pp.124~ (2016)
52. Savitz J, "Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder", Neuropsychopharmacology, 40, pp.463~471 (2015)
53. Meier TB, "Smaller dentate gyrus and CA2 and CA3 volumes are associated with kynurenine metabolites in collegiate football athletes", J Neurotrauma, 33, pp.1349~1357 (2016)
54. Savitz J, "Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder", Psychoneuroendocrinology, 52, pp.200~211 (2015)
55. Young KD, "Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression", Brain Behav Immun, 56, pp.335~342 (2016)
56. Brundin L, "Role of inflammation in suicide : from mechanisms to treatment", Neuropsychopharmacology, 42, pp.271~283 (2017)
57. Serafini G, "Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality : a systematic review", CNS Neurol Disord Drug Targets, 16, pp.440~453 (2017)
58. Bay-Richter C, "A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality", Brain Behav Immun, 43, pp.110~117 (2015)
59. Steiner J, "Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?", J Neuroinflammation, 8, pp.94~ (2011)
60. Brundin L, "An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation", Transl Psychiatry, 6, pp.e865~ (2016)
61. Bryleva EY, "Kynurenine pathway metabolites and suicidality", Neuropharmacology, 112(Pt B), pp.324~330 (2017)
62. Listunova L, "Cognitive impairment along the course of depression : non-pharmacological treatment options", Psychopathology, 51, pp.295~305 (2018)
63. Zhou Y, "Crosssectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder", Psychoneuroendocrinology, 101, pp.72~79 (2019)
64. Konstantinou G, "Kynurenine pathway in bipolar disorder", Psychiatriki, 29, pp.338~348 (2018)
65. Huang X, "Increased plasma kynurenic acid levels are associated with impaired attention", vigilance and social cognition in patients with schizophrenia, 2020, pp.16, 263~271
66. Albuquerque EX, "Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges", Biochem Pharmacol, 85, pp.1027~1032 (2013)
67. Rossi F, "The synthesis of kynurenic acid in mammals : an updated kynurenine aminotransferase structural katalogue", Front Mol Biosci, 6, pp.7~ (2019)
68. Kim H, "Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression", J Clin Invest, 122, pp.2940~2954 (2012)
69. Huang L, "Virus infections incite pain hypersensitivity by inducing indoleamine 2, 3 dioxygenase", PLoS Pathog, 12, pp.e1005615~ (2016)
70. Laumet G, "Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain", Brain Behav Immun, 66, pp.94~102 (2017)
71. Benatti C, "Disease-induced neuroinflammation and depression", CNS Neurol Disord Drug Targets, 15, pp.414~433 (2016)
72. Sakurai M, "Serum metabolic profiles of the tryptophan-kynurenine pathway in the high risk subjects of major depressive disorder", Sci Rep, 10, pp.1961~ (2020)
73. Fujigaki H, "Linking phencyclidine intoxication to the tryptophan-kynurenine pathway : therapeutic implications for schizophrenia", Neurochem Int, 125, pp.1~6 (2019)
74. Kehr J, "Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity", Psychopharmacology(Berl), 235, pp.1593~1607 (2018)
75. Flores-Barrera E, "Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the α7nACh negative modulator kynurenic acid", J Neurosci, 37, pp.7921~7929 (2017)
76. Kozak R, "Reduction of brain kynurenic acid improves cognitive function", J Neurosci, 34, pp.10592~10602 (2014)
77. Buckley PF, "Neuroinflammation and schizophrenia", Curr Psychiatry Rep, 21, pp.72~ (2019)
78. Laskaris LE, "Microglial activation and progressive brain changes in schizophrenia", Br J Pharmacol, 173, pp.666~680 (2016)
79. Gos T, "Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients", Brain Behav Immun, 41, pp.59~64 (2014)
80. Condray R, "3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia", Int J Neuropsychopharmacol, 14, pp.756~767 (2011)
81. Johansson AS, "Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia : cytokine challenge increases production of 3-hydroxykynurenine", J Psychiatr Res, 47, pp.1815~1823 (2013)
82. Chiappelli J, "Salivary kynurenic acid response to psychological stress : inverse relationship to cortical glutamate in schizophrenia", Neuropsychopharmacology, 43, pp.1706~1711 (2018)
83. Bortz DM, "Oral administration of a specific kynurenic acid synthesis(KAT II)inhibitor attenuates evoked glutamate release in rat prefrontal cortex", Neuropharmacology, 121, pp.69~78 (2017)
84. Dounay AB, "PF-04859989 as a template for structure-based drug design : identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency", Bioorg Med Chem Lett, 23, pp.1961~1966 (2013)
85. Mándi Y, "The kynurenine system and immunoregulation", J Neural Transm(Vienna), 119, pp.197~209 (2012)
86. Worton SA, "The kynurenine pathway; a new target for treating maternal features of preeclampsia", Placenta, 84, pp.44~49 (2019)
87. Badawy AA, "Tryptophan metabolism, disposition and utilization in pregnancy", Biosci Rep, 35, pp.e00261~ (2015)
88. Badawy AA, "The end of the road for the tryptophan depletion concept in pregnancy and infection", Clin Sci(Lond), 130, pp.1327~1333 (2016)
89. Weyh C, "Physical activity and diet shape the immune system during aging", Nutrients, 12, pp.622~ (2020)
90. Duan KM, "The role of tryptophan metabolism in postpartum depression", Metab Brain Dis, 33, pp.647~660 (2018)
91. Baïlara KM, "Decreased brain tryptophan availability as a partial determinant of post-partum blues", Psychoneuroendocrinology, 31, pp.407~413 (2006)
92. Quan C, "The role of kynurenine pathway and kynurenic aminotransferase alleles in postpartum depression following cesarean section in Chinese women", Brain Behav, 10, pp.e01566~ (2020)
93. Comai S, "Tryptophan in health and disease", Adv Clin Chem, 95, pp.165~218 (2020)
94. Agus A, "Gut microbiota regulation of tryptophan metabolism in health and disease", Cell Host Microbe, 23, pp.716~724 (2018)
95. Laurans L, "Genetic deficiency of indoleamine 2, 3-dioxygenase promotes gut microbiota-mediated metabolic health", Nat Med, 24, pp.1113~1120 (2018)
96. Alper Evrensel, "Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders", Clinical Psychopharmacology and Neuroscience, 14(3), pp.231~237 (2016), 대한정신약물학회
97. Favennec M, "The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation", Obesity(Silver Spring), 23, pp.2066~2074 (2015)
98. Song P, "Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases", Cell Mol Life Sci, 74, pp.2899~2916 (2017)
99. Castro-Portuguez R, "Kynurenine pathway, NAD＋synthesis, and mitochondrial function : targeting tryptophan metabolism to promote longevity and healthspan", Exp Gerontol, 132, pp.110841~ (2020)
100. Kim BJ, "Clinical insights into the kynurenine pathway in age-related diseases", Exp Gerontol, 130, pp.110793~ (2020)
101. Zádori D, "Alzheimer’s disease : recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines", J Alzheimers Dis, 62, pp.523~547 (2018)
102. Lovelace MD, "Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases", Neuropharmacology, 112(Pt B), pp.373~388 (2017)
103. Lim CK, "Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease", Prog Neurobiol, 155, pp.76~95 (2017)
104. Achtyes E, "Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression", Brain Behav Immun, 83, pp.239~247 (2020)
105. Roman M, "Novel neuroimmunologic therapeutics in depression : a clinical perspective on what we know so far", Brain Behav Immun, 83, pp.7~21 (2020)
106. Dounay AB, "Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway", J Med Chem, 58, pp.8762~8782 (2015)
107. Jacobs KR, "Major developments in the design of inhibitors along the kynurenine pathway", Curr Med Chem, 24, pp.2471~2495 (2017)
108. Park LT, "A randomized trial of the N-Methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression", Int J Neuropsychopharmacol, 23, pp.417~425 (2020)
109. Walker AK, "Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice", Mol Psychiatry, 24, pp.1523~1532 (2019)
110. Guloksuz S, "The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway", Brain Behav Immun, 48, pp.48~52 (2015)
111. Wu Y, "Kynurenine pathway changes in late-life depression", J Affect Disord, 235, pp.76~81 (2018)
112. Zhou Y, "Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression", Brain Behav Immun, 74, pp.205~212 (2018)
113. Agudelo LZ, "Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression", Cell, 159, pp.33~45 (2014)
114. Schlittler M, "Endurance exercise increases skeletal muscle kynurenine aminotransferases and plasma kynurenic acid in humans", Am J Physiol Cell Physiol, 310, pp.C836~C840 (2016)
115. Savitz JB, "Treatment of bipolar depression with minocycline and", or aspirin : an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial, 2018, pp.8, 27~

관련 논문AI추천